Skip to main content
ASTH logo

ASTH · Astrana Health, Inc.

Track ASTH — free
$28.68 -0.97 (-3.27%) At close · Nov 19
Market Cap
$1.60B
Shares
55.80M
Volume · Nov 19 369.66K Avg daily vol (3M) 374.06K

Price & Indicators

 

Key stats

Close
$28.68
Open
$29.49
Day range
$27.98–30.31
52-week closing range
$18.16–49.81
Average volume, 30 days
361K
Short interest
3.0M · 5.4% of shares · 12.3 days
Short volume, last session
58%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 6
Price history
Jan 2020 to Nov 2026

Up next

Mar 1, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue and profit surge as cyber incident remains unresolved

Astrana Health, Inc. reported nine-month revenue of $2,961.2 million, up 33%, and attributable net income of $47.1 million, up $30.6 million. The full impact of the cybersecurity incident remains unquantified.

Revenue $1.02B ▲ 7.1% Net income $12.95M ▲ 3372.4% Diluted EPS $0.26 ▲ 2500.0%
Read from the MD&A section
3 source passages
Revenue for the nine months ended September 30, 2026 was $2,961.2 million, as compared to $2,231.2 million for the nine months ended September 30, 2025, an increase of $730.0 million or 33%. Our net income attributable to Astrana Health, Inc. for the nine months ended September 30, 2026 was $47.1 million, as compared to $16.5 million for the same period in 2025, an increase of $30.6 million. At this time, we are unable to estimate the full potential impact of the incident on our business strategy, operations, financial condition, or results of operations Open the document at this passage
Nov 5
Earnings call
Record results with full-year guidance maintained

Astrana delivered record third-quarter revenue of $1.02 billion and adjusted EBITDA of $77.2 million, up 7% and 13%, respectively. It maintained full-year revenue guidance of $3.9 billion to $4 billion and adjusted EBITDA guidance of $261 million to $274 million.

2 source passages
Revenue in the third quarter reached a record $1.02 billion, up 7% year-over-year, and adjusted EBITDA was a record $77.2 million, up 13% year-over-year, and near the high end of guidance. We now expect revenue of $3.9 billion to $4 billion, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million. Open the document at this passage
Nov 5
Current report 8-K
Revenue hits $1,023.6 million as adjusted EBITDA reaches $77.2 million

Astrana Health reported third-quarter revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million and adjusted EBITDA of $77.2 million, up 13%.

Financial results, Regulation FD disclosure Read from the first part of this long document
2 source passages
Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the third quarter ended September 30, 2026. Reports record revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million, up 1,782% year-over-year, and record adjusted EBITDA^(1)^ of $77.2 million, up 13% year-over-year for the three months ended September 30, 2026 Open the document at this passage
Sep 23
Current report 8-K
Regulation FD disclosure

Astrana Health updated its corporate presentation on September 23, 2026, raising FY2026 Adjusted EBITDA guidance to $255 – $280M and reaffirming revenue guidance of $3,800 – $4,100M and free cash flow guidance of $105 – $132.5M.

Sep 23
Current report 8-K Events of Sep 22
Material cybersecurity incident

Astrana Health, Inc. deemed a social-engineering incident material on September 22, 2026; it believes private or confidential information may have been accessed, but cannot estimate impact and does not expect a material effect on financial condition or results of operations.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.91B
Trailing 12 months
Net income (TTM)
$53.13M
Trailing 12 months
Revenue growth YoY
+7.1%
Year over year
Operating margin
3.1%
Trailing 12 months
P / E (TTM)
26.8
Trailing earnings · reciprocal yield 3.7%
FCF yield
6.2%
TTM · current market cap
Return on invested capital
5.9%
Trailing 12 months
Net cash
−$529.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
+30.2%
Trailing year
Short interest
5.4%
Latest settlement · 12.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Astrana delivered record third-quarter revenue and adjusted EBITDA, with organic earnings growth, favorable medical-cost performance, expanding full-risk exposure, new partnerships and strong cash generation and deleveraging. The main risks are Medicaid attrition, trend pressure and 2027 headwinds, along with a lower-profitability fourth quarter, an unresolved cyber incident and continued remediation of a material weakness.

Bullish
  • + Third-quarter revenue reached a record $1,023.6 million, up 7% year-over-year, while adjusted EBITDA reached a record $77.2 million, up 13%.
  • + Adjusted EBITDA growth was organic, driven by cohort maturation, improved medical-cost performance and operating efficiencies.
  • + The company expects approximately 82% of capitation revenue to be generated under full-risk arrangements by year-end, up from 76% at year-end 2025.
  • + Astrana expanded its footprint through a Georgia acquisition, two care-enablement clients and several new Medicare Advantage payer partnerships effective January 1, 2027.
  • + Consolidated medical-cost trend year to date is slightly better than the approximately 5.2% assumption embedded in full-year guidance.
  • + The company generated approximately $105 million of free cash flow through the first nine months and reduced trailing net leverage to approximately 2.2 times.
Bearish
  • − Medicaid attrition is expected to be at the middle-to-high-end of the original 10% to 15% assumption.
  • − Management expects a mid-single-digit net EBITDA-growth headwind from Medicaid and a 10% to 15% membership decline in 2027.
  • − Medicaid medical-cost trend is above initial expectations, and management is beginning to see adverse selection among remaining members.
  • − Management expects the fourth quarter to be the year's lowest quarter in terms of profitability.
  • − A cyber incident involving criminal activity remains under investigation with law enforcement.
  • − The company is still remediating a previously disclosed material weakness in internal control over financial reporting.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −17%
below
Price vs 50-day avg −20%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −25%
trailing
6-month return −24%
trailing
YTD return +16%
this year
Relative strength −18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $36 › 200d $34 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.37% of shares out · ▼ -0.5% MoM · 12.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
220 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Fair
Revenue growth +46%
Y/Y
Gross margin 0%
contracting
EPS growth −49%
Y/Y
Free cash flow $104.5M
Valuation P/E 26.8
rich
Buyback $83.1M
remaining
Balance sheet $609.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −42%
past year
ATR 7.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 8
Latest guidance · from the Earnings Call filed Nov 5, 2026
full-year 2026
Free cash flow Maintained $107.5M – $130M
Aug 6, 2026 $105M – $132.5M changed to Nov 5, 2026 $107.5M – $130M
by year-end 2026
Capitation revenue generated under full-risk arrangements 82%
full-year
Revenue Maintained $3.9B – $4B
Aug 6, 2026 $3.8B – $4.1B changed to Nov 5, 2026 $3.9B – $4B
prior FY $3.18B midpoint +24.1% Y/Y
Adjusted EBITDA Non-GAAP Maintained $261M – $274M
Aug 6, 2026 $255M – $280M changed to Nov 5, 2026 $261M – $274M
fourth quarter
Revenue $939M – $1.04B
prior qtr $1.02B midpoint −3.3% QoQ
Adjusted EBITDA Non-GAAP $48.5M – $61.5M
Previous outlook earlier release · from the 8-K filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Free cash flow · Year Ending December 31, 2026 $105M – $132.5M
Prior guidance period ended · from the Earnings Call filed Aug 6, 2026
Revenue · third quarter of 2026 $1B – $1.03B
Guided vs delivered · last 8 settled
Revenue third quarter of 2026
guided $1B – $1.03B
$1.02B In line
Revenue second quarter of 2026
guided $965M – $1B
$972.52M In line
EPS - diluted year ending December 31, 2024
guided $1.28 – $1.52
$0.90 Miss −35.7%
Total revenue full year 2023
guided $1.34B – $1.39B
$1.39B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−17% Bearish
Price vs 50-day avg
−20% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $36 › 200d $34 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.37% of shares out · ▼ -0.5% MoM · 12.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
220 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $18 Now $29 · 33% Range high $50
vs 200-day avg -17% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Annual Wellness Visit (AWV) program reach of eligible members 65% Year to date 2026 —
Free cash flow non-GAAP $105.4M nine months ended September 30, 2026 —
G&A expense 6.2% Year-to-date 2026 —
YTD Free Cash Flow non-GAAP $105.45M nine months ended September 30, 2026 —
Q2 2026 capitation revenue from full-risk arrangements 81% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ASTH
Astrana Health, Inc.
this stock
$1.60B +15.6% +45.9% 26.8 5.4%
HCA
HCA Healthcare, Inc.
$96.16B -1.4% +7.1% 15.3 2.3%
FSNUY
Fresenius SE & Co. KGaA
$32.17B -0.3% — — 0.0%
THC
Tenet Healthcare Corp
$20.98B +32.6% +0.9% 7.6 2.2%
EHC
Encompass Health Corp
$12.98B +24.6% +10.5% 20.7 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
220
% held
61.8%
Net QoQ
+2.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
245
View
Short & Settlement
Short Interest Falling
Shares short
3.0M
Days to cover
12.3d
Change
-15.4K sh
View
Short Volume
Short vol %
58%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
6.0K
Value
$226.4K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
39.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Judy Chu
Amount
$100.0K–$250.0K
Traded
Aug 19, 2025
View
Financials
Financials
Revenue (FY)
$3.2B
Net income (FY)
$22.5M
EPS diluted
$0.46
View
Buybacks
Authorized
$100.0M
Remaining
$83.1M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
28

Astrana Health, Inc. reported nine-month revenue of $2,961.2 million, up 33%, and attributable net income of $47.1 million, up $30.6 million. The full impact of the cybersecurity incident remains unquantified.

View
Exempt Offerings
Offering
$1.4M
Filed
Nov 21, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Foothill Regional Medical Center…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
ASTH -9.7% -24.6% -24.1% -21.5% +15.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -4.3% -18.3% -18.4% -16.2% +10.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$100.00M
Spent (derived)
$16.90M
Remaining
$83.10M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1083446 CUSIP 03763A207 13F (30d) 227 filings 207 filers Visit website Investor relations